News Releases

SEATTLE, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the closing of its upsized initial public offering of 27,025,000 shares of its common stock at a public offering price of

SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of its upsized initial public offering of 23,500,000 shares of its common stock at a public offering

Josh Bilenker, M.D., Alise Reicin, M.D., and Michelle Seitz, CFA, join Sana Board of Directors SEATTLE, Jan. 8, 2021 /PRNewswire/ -- Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Josh Bilenker, M.D., Alise Reicin, M.D.,

SEATTLE, Jan. 6, 2021 /PRNewswire/ -- Sana Biotechnology, Inc. (Sana), focused on creating and delivering engineered cells as medicines, announced today that Ke Liu, M.D., Ph.D., has joined the senior leadership team as Sana's Head of Regulatory Affairs & Strategy. Dr.